Form 4: Lisata Therapeutics Director Azab Mohammad Reports Stock Transactions

Director Mohammad Azab of Lisata Therapeutics reported the acquisition of 15,789 restricted stock units and the holding of 74,469 shares.

Summary

• Mohammad Azab, a director at Lisata Therapeutics, reported a transaction on January 9, 2025.
• The transaction involved the acquisition of 15,789 restricted stock units.
• These restricted stock units were granted under the company's 2018 Equity Incentive Compensation Plan.
• The units will vest on January 9, 2026.
• Mr. Azab also holds 74,469 shares, which includes 22,189 unvested restricted stock units.

Sentiment

Score: 7

Explanation: The document is a routine filing of a stock transaction by a director, which is generally neutral to positive. The grant of stock units is a positive sign of alignment between management and shareholders.

Positives

• The grant of restricted stock units to a director aligns with typical incentive compensation practices.
• The vesting period of one year may encourage long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the holdings and transactions of company directors.

Comparison to Industry Standards

• The granting of restricted stock units is a common practice for incentivizing directors and executives in publicly traded companies.
• The vesting period of one year is also a typical timeframe for such grants.
• Similar filings can be seen across the biotechnology sector, with companies like Amgen, Gilead, and Regeneron regularly reporting insider transactions.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director stock ownership.
• The vesting of restricted stock units may align the director's interests with those of shareholders.

Key Dates

Keywords

Lisata Therapeutics, Director, Stock Transaction, Restricted Stock Units, Equity Incentive Plan, Form 4, Beneficial Ownership